New criteria for the following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List effective June 1, 2017.
The following was reviewed by the pan Canadian Oncology Drug Review (pCODR) recommended for coverage with criteria:
COTELLIC (Cobimetinib) 20mg DIN 02452340
In combination with vemurafenib, for the treatment of patients with previously untreated BRAF V600 mutation-positive unresectable stage III or stage IV melanoma who have a good performance status. Treatment should continue until unacceptable toxicity or disease progression. If brain metastases are present, patients should be asymptomatic or have stable symptoms.
Approval Period: 6 months
Dosing: 60mg once daily for 21 days every 28 days
pCODR Expert Review Committee (pERC) recommendations can be viewed at www.cadth.ca